Infectious Enteritis Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Infectious Enteritis Treatment Market Analysis
The Infectious Enteritis Treatment market is anticipated to grow with a CAGR of nearly 4.9% during the forecast period.
The COVID-19 pandemic had a significant impact on the infectious enteritis market. According to an article published by Clinical Medicine in March 2022, acute gastrointestinal side effects were reported with COVID-19 infection and were estimated to affect around 17% of patients. According to an article published by the Harvard Gazette in November 2021, 60% of patients infected with SARS-CoV-2 also report gastrointestinal symptoms such as nausea, diarrhea, and stomach pain. With an increase in these intestinal enteritis symptoms, the demand for its treatment increase. Therefore, the increasing number of cases of COVID-19 further led to an increased number of cases of infectious enteritis, and thus the market witnessed considerable growth during the pandemic. However, the market is witnessing stabilized growth currently owing to the decrease in COVID-19 cases and the increase in these intestinal enteritis cases, and is expected to project a similar trend over the coming years as per the analysis.
Factors such as the rising population with irritable bowel syndrome (IBS) and diarrhea cases due to infectious enteritis and intensive research and development activities, and Increasing FDA approvals of infectious enteritis treatment drugs are expected to drive the growth of the market over the forecast period. For instance, according to an article published by the Middle East Journal of Digestive Diseases in July 2022, it was estimated that the incidence of IBS is 38.5 per 10,000 persons per year, and the prevalence has been reported to be 10-17% in the general population. Furthermore, according to an article published by BMC Medicine, in March 2022, IBS patients are subtyped based on bowel habit profile into diarrhea (IBS-D), constipation (IBS-C), mixed (IBS-M) or indeterminate, and approximately 10-20% of all cases develop after an episode of acute gastroenteritis. Thus, increase in the population with IBS and diarrhea cases due to infectious enteritis, the demand for its treatment increase, thereby driving the growth of the market over the forecast period.
Additionally, various initiatives taken by the key market players, such as product launches, mergers, acquisitions, and partnerships, are expected to boost the market's growth during the forecast period. For instance, in November 2021, an interdisciplinary panel of infectious disease clinicians and public health experts led by the Center for Disease Dynamics, Economics & Policy (CDDEP) and the Africa CDC released the first edition of the African Antibiotic Treatment Guidelines for Common Bacterial Infections and Syndromes. Such an initiative is expected to drive the growth of the market.
The factors mentioned above are expected to drive the market's growth worldwide. However, several adverse effects associated with the treatment of infectious enteritis and a lack of awareness among people in developing countries are expected to restrain the growth of the studied market over the forecast period.
Infectious Enteritis Treatment Market Trends
This section covers the major market trends shaping the Infectious Enteritis Treatment Market according to our research experts:
Antibiotics shows Lucrative Opportunity in the Infectious Enteritis Treatment Market
Antibiotics are medicines that fight bacterial infections. These are effective against a wide variety of enteric infections in adults, including shigellosis, salmonellosis, typhoid fever, cholera, and many more. Factors such as the rising population with these infections due to infectious enteritis are expected to drive the market's growth. For instance, according to an article published by the National Library of Medicine, in April 2021, acute gastroenteritis (AGE) is one of the most common bacterial infectious diseases clinicians face in daily practice. Globally, bacterial enteric pathogens cause billions of infections yearly with tremendous morbidity. In the United States alone it is estimated that there are nearly 200 million cases of AGE annually. Thus with an increase in bacterial enteritis, the demand for antibiotics increases, thereby driving the growth of the market.
The companies actively participate in new product launch developments and collaborations to expand their footprint. For instance, in June 2022, Shionogi & Co., Ltd. and the Global Antibiotic Research and Development Partnership (GARDP) signed the execution of a license and technology transfer agreement and, with the Clinton Health Access Initiative (CHAI), a collaboration agreement that aims to significantly transform the landscape of access to antibiotics for countries around the world. Such development is expected to drive the growth of the market.
Thus, the factors mentioned above are likely to contribute to the segment's growth over the forecast period.
North America Show a Significant Market Growth in the Infectious Enteritis Treatment Market
North America is expected to dominate the infectious enteritis treatment market, and it is mainly driven due to the increasing prevalence of pathogens causing infectious enteritis and growing investment in healthcare. For instance, according to the CDC updated in December 2022, it is estimated Salmonella bacteria causes about 1.35 million infections and 26,500 hospitalizations in the United States every year. Therefore, the growing incidence rate of salmonella bacteria among people is expected to increase the demand for effective treatment, fueling the target market growth in the studied period.
Furthermore, the United States holds the largest market share in the North American region owing to factors such as the presence of a large number of market players manufacturing medications for infectious enteritis. In addition to this, several market players are engaged in product launches, thereby contributing to the region's growth. For instance, in March 2021, Knight Therapeutics Inc. commercially launched IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Such development is expected to drive the regional growth over the forecast period.
As a result, all the aforementioned factors are likely to contribute to this region's strong growth over the forecast period.
Infectious Enteritis Treatment Industry Overview
The infectious enteritis treatment market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known, including Actelion Pharmaceuticals, BioGaia, Bristol-Myers Squibb, GlaxoSmithKline plc, Mayne Pharma, Novartis Pharmaceuticals, Pfizer Inc., Teva Pharmaceuticals, among others.
Infectious Enteritis Treatment Market Leaders
-
Novartis Pharmaceuticals
-
Teva Pharmaceuticals
-
Pfizer Inc.
-
GlaxoSmithKline plc.
-
Mayne Pharma
*Disclaimer: Major Players sorted in no particular order
Infectious Enteritis Treatment Market News
- July 2022: Bausch Health Companies Inc. and its gastroenterology business Salix Pharmaceuticals reported that the U.S. District Court of Delaware issued an Oral Order in the matter of Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc. regarding the infringement and validity of certain U.S. Patents protecting the composition and use of XIFAXAN (rifaximin) 550 mg tablets for the treatment of irritable bowel syndrome with diarrhea (IBS-D) and reduction in risk of overt hepatic encephalopathy (HE) recurrence.
- April 2022: Ardelyx, Inc. received the USFDA for IBSRELA. This is an NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
Infectious Enteritis Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions & Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 The rising population with IBS and diarrhoea cases due to infectious enteritis
- 4.2.2 Intensive research and development activities and Increasing FDA approvals of infectious enteritis treatment drugs
-
4.3 Market Restraints
- 4.3.1 Several adverse effects associated with the treatment of infectious enteritis
- 4.3.2 Lack of awareness among people in developing countries
-
4.4 Porter Five Forces
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Route of Administration
- 5.1.1 Oral
- 5.1.2 Injectables
-
5.2 By Drug Type
- 5.2.1 Antibiotics
- 5.2.2 Antivirals
- 5.2.3 Others
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Johnson & Johnson
- 6.1.2 BioGaia
- 6.1.3 Bristol-Myers Squibb
- 6.1.4 GlaxoSmithKline plc
- 6.1.5 Mayne Pharma
- 6.1.6 Novartis AG
- 6.1.7 Pfizer Inc.
- 6.1.8 Teva Pharmaceuticals
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityInfectious Enteritis Treatment Industry Segmentation
As per the scope of this report, enteritis refers to the inflammation of the small intestine. Infectious enteritis is the most common type and includes bacterial and viral enteritis. Eating or drinking contaminated food or water causes bacterial enteritis. Viral enteritis also occurs through eating or drinking contaminated food or water and after contact with someone who has the virus. Viral enteritis usually goes away within a few days. The Infectious Enteritis Treatment Market is Segmented By Route of Administration (Oral and Injectables), Drug Type (Antibiotics, Antivirals, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Route of Administration | Oral | |
| Injectables | ||
| By Drug Type | Antibiotics | |
| Antivirals | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Infectious Enteritis Treatment Market Research FAQs
What is the current Infectious Enteritis Treatment Market size?
The Infectious Enteritis Treatment Market is projected to register a CAGR of 4.90% during the forecast period (2024-2029)
Who are the key players in Infectious Enteritis Treatment Market?
Novartis Pharmaceuticals , Teva Pharmaceuticals , Pfizer Inc., GlaxoSmithKline plc. and Mayne Pharma are the major companies operating in the Infectious Enteritis Treatment Market.
Which is the fastest growing region in Infectious Enteritis Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Infectious Enteritis Treatment Market?
In 2024, the North America accounts for the largest market share in Infectious Enteritis Treatment Market.
What years does this Infectious Enteritis Treatment Market cover?
The report covers the Infectious Enteritis Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Infectious Enteritis Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Europe Access Control Hardware Industry Report
Statistics for the 2024 Europe Access Control Hardware market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Access Control Hardware analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
